Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Adamis Pharmaceuticals, Immunomedics and Three Other Stocks Are Deep in Red Today?

Markets are trading higher on Monday, as HSBC Holdings PLC said in a report earlier today that the markets are poised to remain bullish. However, some stocks are deep in the red today, including Adamis Pharmaceuticals Corp (NASDAQ:ADMP), AbbVie Inc (NYSE:ABBV), ProNAi Therapeutics Inc (NASDAQ:DNAI), Immunomedics, Inc. (NASDAQ:IMMU) and Ocular Therapeutix Inc (NASDAQ:OCUL). Let’s examine the factors hurting these stocks today and see what smart money investors think about these stocks.

At Insider Monkey, we track around 760 hedge funds and institutional investors. Through extensive backtests, we have determined that imitating some of the stocks that these investors are collectively bullish on, can help retail investors generate double digits of alpha per year. The key is to focus on the small-cap picks of these funds, which are usually less followed by the broader market and allow for larger price inefficiencies (see the details here).

Adamis’ Epinephrine Drug Fails to Get Approval

Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s stock has plunged by more than 50% today after the company received a Complete Response Letter (CRL) by the US Food and Drug Administration (FDA) regarding its epinephrine drug for severe allergic reactions. The FDA has advised the San Diego based company to increase its human factors and product stress testing in order to get an NDA for the drug. Only four funds from our database were long Adamis Pharmaceuticals Corp (NASDAQ:ADMP) at the end of the first quarter of 2016. Jeffrey Jay and David Kroin’s Great Point Partners owns more than 2.1 million shares of the company, according to its latest 13F filing.

Most Affordable Medical Schools in Europe

Investors Still Not Impressed By AbbVie’s Cancer Drug

AbbVie Inc (NYSE:ABBV) impressed with the results of its lung cancer drug Rova T on Sunday, but several reports depict that investors are still not happy with the company’s decision to spend a whopping $5.8 billion to buy Stemcentrx, the company which started the production of Rova T. According to the results announced by the company, 11 out of 60 patients experienced shrinkage of tumor, and 41 patients achieved a clinical benefit due to Rova T. However, according to Barclays’ analyst Geoff Meacham, investors were expecting more from the drug. He thinks that Rova T only showed a “modest” incremental median overall survival benefit and added AbbVie’s rival Bristol-Myers Squibb Co (NYSE:BMY) is still a winner in the eyes of investors. AbbVie’s stock has declined more than 4% so far today. From our system, 65 hedge funds had approximately $5.2 billion worth AbbVie Inc (NYSE:ABBV)’s stock at the end of March. Julian Baker and Felix Baker’s Baker Bros. Advisors is one of the biggest shareholders with more than 14 million shares.

On the next page, we will discuss ProNAi, Immunomedics and Ocular Therapeutix.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.